NCT00332774View on ClinicalTrials.gov

Nevanac 3-Month Safety Study With QID Dosing

PHASE3CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Cataract
Interventions
DRUG

Nepafenac ophthalmic solution 0.1%

1 drop 4 times daily for 90 days

DRUG

Ketorolac Tromethamine ophthalmic solution 0.4%

1 drop 4 times daily for 90 days

OTHER

Nepafenac ophthalmic suspension vehicle

Trial Locations (1)

76134

Contact Alcon for Trial Locations, Fort Worth

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00332774 - Nevanac 3-Month Safety Study With QID Dosing | Biotech Hunter | Biotech Hunter